Breve descripción
Study WAL0921-02 is an adaptive, prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate WAL0921 in subjects with glomerular kidney diseases and proteinuria
Médico del ensayo / Coordinador del estudio
Nikolas Arvis
Estimated Enrollment
96
Estimated End Date
April 2027
Trial is for people with
FSGS, TR-MCD, IgAN, PMN, and DN
Study Goal
The goal of Study WAL0921-02 is to evaluate the safety, efficacy, PK, and PD of WAL0921 in subjects with DN and rare glomerular kidney ...
What is involved for the patient?
Subjects participating in the study must complete screening evaluations, participate in planned study-related assessments on ...
About the drug or intervention
WAL0921, an anti-soluble urokinase plasminogen activator receptor (anti-suPAR) humanized immunoglobulin (Ig)G1 monoclonal antibody, is ...